Related references
Note: Only part of the references are listed.A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease
W. Reinisch et al.
GUT (2006)
Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
D. W. Hommes et al.
GUT (2006)
Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy
C Cuffari et al.
DIGESTIVE DISEASES AND SCIENCES (2004)
The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures
J Agnholt et al.
CYTOKINE (2003)
Share Paper
